STEMIRAC Market Summary

Key Factors Driving STEMIRAC Growth

1. First-in-class regenerative therapy with no approved pharmacological competitors

STEMIRAC, developed by Nipro Corporation in collaboration with Sapporo Medical University, received conditional and time-limited approval from Japan's PMDA in December 2018 for improving neurological symptoms and functional impairment associated with spinal cord injury. It remains the only commercially available regenerative medicine product specifically approved for traumatic SCI, providing a significant first-mover advantage in a disease where treatment is otherwise limited to surgery and rehabilitation.

2. Large unmet medical need supports long-term adoption

According to Nipro's corporate disclosures, approximately 6,000 new spinal cord injury cases occur annually in Japan, while more than 100,000 people live with chronic SCI-related disabilities. Despite advances in supportive care, no disease-modifying drug has been available outside STEMIRAC. The therapy's ability to promote neurological recovery using autologous bone marrow-derived MSCs addresses a substantial unmet need and supports continued uptake at specialized treatment centers.

3. Progress toward full regulatory approval enhances physician confidence

Following seven years of post-marketing surveillance required under Japan's conditional approval framework, Nipro submitted a full marketing approval application in November 2025 after completing comparative post-marketing studies evaluating safety and efficacy. Successful conversion from conditional to full approval would strengthen physician confidence, expand reimbursement certainty, and facilitate broader clinical adoption.

4. Expansion of treatment infrastructure and additional indications

Nipro has stated that increasing the number of certified treatment centers across Japan is a key commercialization strategy to improve patient access. In parallel, the company is conducting clinical development to extend STEMIRAC into chronic spinal cord injury and amyotrophic lateral sclerosis (ALS), potentially expanding the addressable patient population and maximizing manufacturing utilization.

5. Government reimbursement and supportive regenerative medicine policies

STEMIRAC is reimbursed under Japan's national health insurance despite its conditional approval, reducing financial barriers for eligible patients. Furthermore, Japan's regenerative medicine framework—including the conditional approval pathway introduced under the Pharmaceuticals and Medical Devices Act—has accelerated commercialization of innovative cell therapies, providing a favorable environment for continued market growth.

STEMIRAC Recent Developments

In 2018, STEMIRAC received conditional market approval from Japan's Pharmaceutical and Medical Devices Agency (PMDA), requiring continued data collection to assess its long-term efficacy and safety. Initially approved for subacute SCI, a corporate clinical trial for chronic SCI was launched in July 2023 to broaden its therapeutic applications. Recognized as a breakthrough product under Japan's SAKIGAKE system in 2016, STEMIRAC represents a significant advancement in regenerative medicine. Developed in collaboration with Sapporo Medical University, it is expected to achieve full approval by December 2025, offering new treatment possibilities for SCI patients.

“STEMIRAC Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of STEMIRAC for approved indication like Spinal cord injuries in the 7MM. A detailed picture of STEMIRAC’s existing usage in anticipated entry and performance in approved indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the STEMIRAC for approved indications. The STEMIRAC market report provides insights about STEMIRAC’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current STEMIRAC performance, future market assessments inclusive of the STEMIRAC market forecast analysis for approved indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of STEMIRAC sales forecasts, along with factors driving its market.

STEMIRAC Drug Summary

STEMIRAC (autologous human bone marrow-derived mesenchymal stem cells; also known as CL2020) is a regenerative cell therapy developed by Nipro Corporation for the treatment of traumatic spinal cord injury. It is manufactured using a patient's own bone marrow-derived mesenchymal stem cells, which are expanded ex vivo and administered as a single intravenous infusion during the subacute phase following injury. The therapy is designed to modulate inflammation, promote neuroprotection, stimulate angiogenesis, and support neuronal repair through the secretion of trophic factors rather than direct cell replacement. STEMIRAC became the world's first approved regenerative medicine product for spinal cord injury when it received conditional and time-limited marketing authorization in Japan in 2018 under the country's accelerated regenerative medicine framework. Clinical studies demonstrated an acceptable safety profile and suggested improvements in motor and sensory function in a subset of patients, although additional post-marketing studies are required to further confirm its long-term efficacy and clinical benefit. STEMIRAC represents an important milestone in regenerative medicine by offering a novel therapeutic approach for patients with limited treatment options following traumatic spinal cord injury. The report provides STEMIRAC’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the STEMIRAC Market Report

The report provides insights into:

• A comprehensive product overview including the STEMIRAC MoA, description, dosage and administration, research and development activities in approved indication like Spinal cord injuries.
• Elaborated details on STEMIRAC regulatory milestones and other development activities have been provided in STEMIRAC market report.
• The report also highlights STEMIRAC‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved indications across the United States, Europe, and Japan.
• The STEMIRAC market report also covers the patents information, generic entry and impact on cost cut.
• The STEMIRAC market report contains current and forecasted STEMIRAC sales for approved indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The STEMIRAC market report also features the SWOT analysis with analyst views for STEMIRAC in approved indications.

Methodology

The STEMIRAC market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

STEMIRAC Analytical Perspective by DelveInsight

• In-depth STEMIRAC Market Assessment

This STEMIRAC sales market forecast report provides a detailed market assessment of STEMIRAC for approved indication like Spinal cord injuries in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted STEMIRAC sales data uptil 2034.

• STEMIRAC Clinical Assessment

The STEMIRAC market report provides the clinical trials information of STEMIRAC for approved indications covering trial interventions, trial conditions, trial status, start and completion dates.

STEMIRAC Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

STEMIRAC Market Potential & Revenue Forecast

• Projected market size for the STEMIRAC and its key indications
• Estimated STEMIRAC sales potential (STEMIRAC peak sales forecasts)
• STEMIRAC Pricing strategies and reimbursement landscape

STEMIRAC Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• STEMIRAC Market positioning compared to existing treatments
• STEMIRAC Strengths & weaknesses relative to competitors

STEMIRAC Regulatory & Commercial Milestones

• STEMIRAC Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

STEMIRAC Clinical Differentiation

• STEMIRAC Efficacy & safety advantages over existing drugs
• STEMIRAC Unique selling points

STEMIRAC Market Report Highlights

• In the coming years, the STEMIRAC market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The STEMIRAC companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence STEMIRAC’s dominance.
• Other emerging products for Spinal cord injuries are expected to give tough market competition to STEMIRAC and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of STEMIRAC in approved indications.
• Analyse STEMIRAC cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted STEMIRAC sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of STEMIRAC in approved indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of STEMIRAC? How strong is STEMIRAC’s clinical and commercial performance?
• What is STEMIRAC’s clinical trial status in each individual indications such as Spinal cord injuries and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the STEMIRAC Manufacturers?
• What are the key designations that have been granted to STEMIRAC for approved indications? How are they going to impact STEMIRAC’s penetration in various geographies?
• What is the current and forecasted STEMIRAC market scenario for approved indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of STEMIRAC in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to STEMIRAC for approved indications?
• Which are the late-stage emerging therapies under development for the treatment of approved indications?
• How cost-effective is STEMIRAC? What is the duration of therapy and what are the geographical variations in cost per patient?